MDV-3100
Overview | |
Catalog # | bs-6433c-2mg-solid |
Product Name | MDV-3100 |
Specifications | |
Storage Buffer | Powder |
Storage Condition | Store in dry, dark place at -20C for 1 year. |
Target | |
Product Information | Molecular Weight: 464.44 Formula: C21 H16 F4 N4 O2 S CAS Number: 915087-33-1 InChi Key: WXCXUHSOUPDCQV-UHFFFAOYSA-N InChi: InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30) Smiles: CC1(C)C(=O)N(C(=S)N1C1=CC(F)=C(C=C1)C(=O)NC)C1C=CC(C#N)=C(C=1)C(F)(F)F Purity: 98.0 Solubility: Soluble in DMSO, not in water Appearance: Solid Power Shelf Life: 1.0 years |
Description | Enzalutamide, also known as MDV3100, is an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, selective androgen receptor modulator MDV3100 inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. In August 2012, the United States (U.S.) Food and Drug Administration (FDA) approved enzalutamide for the treatment of castration-resistant prostate cancer. |